vs
Side-by-side financial comparison of Scilex Holding Co (SCLX) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
cbdMD, Inc. is the larger business by last-quarter revenue ($5.0M vs $4.8M, roughly 1.0× Scilex Holding Co). cbdMD, Inc. runs the higher net margin — -5.6% vs -961.9%, a 956.3% gap on every dollar of revenue. On growth, cbdMD, Inc. posted the faster year-over-year revenue change (-1.9% vs -67.8%). Over the past eight quarters, cbdMD, Inc.'s revenue compounded faster (7.1% CAGR vs -33.6%).
Scilex Holding Co is a commercial-stage biopharmaceutical firm focused on developing and commercializing innovative non-opioid pain management therapies for acute and chronic pain segments. It primarily serves the US market, offering prescription and over-the-counter pain relief solutions for patients and healthcare providers.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
SCLX vs YCBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $5.0M |
| Net Profit | $-46.1M | $-283.1K |
| Gross Margin | 45.5% | 59.8% |
| Operating Margin | -2317.8% | -5.7% |
| Net Margin | -961.9% | -5.6% |
| Revenue YoY | -67.8% | -1.9% |
| Net Profit YoY | -613.7% | -1975.7% |
| EPS (diluted) | $-4.63 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.8M | $5.0M | ||
| Q3 25 | $10.6M | $4.7M | ||
| Q2 25 | $9.9M | $4.6M | ||
| Q1 25 | $5.0M | $4.7M | ||
| Q4 24 | $14.9M | $5.1M | ||
| Q3 24 | $14.4M | $4.6M | ||
| Q2 24 | $16.4M | $5.2M | ||
| Q1 24 | $10.9M | $4.4M |
| Q4 25 | $-46.1M | $-283.1K | ||
| Q3 25 | $-257.8M | $-680.0K | ||
| Q2 25 | $-44.0M | $-895.3K | ||
| Q1 25 | $-26.1M | $-480.8K | ||
| Q4 24 | $-6.5M | $15.1K | ||
| Q3 24 | $-4.4M | $-152.8K | ||
| Q2 24 | $-37.6M | $459.7K | ||
| Q1 24 | $-24.4M | $-3.0M |
| Q4 25 | 45.5% | 59.8% | ||
| Q3 25 | 68.5% | 58.8% | ||
| Q2 25 | 66.9% | 61.5% | ||
| Q1 25 | 72.3% | 62.3% | ||
| Q4 24 | 68.5% | 66.5% | ||
| Q3 24 | 73.9% | 53.9% | ||
| Q2 24 | 73.2% | 65.8% | ||
| Q1 24 | 64.7% | 59.0% |
| Q4 25 | -2317.8% | -5.7% | ||
| Q3 25 | -1766.2% | -14.5% | ||
| Q2 25 | -207.2% | -19.6% | ||
| Q1 25 | -557.5% | -10.2% | ||
| Q4 24 | -190.5% | -1.7% | ||
| Q3 24 | -138.0% | -6.9% | ||
| Q2 24 | -95.4% | -7.4% | ||
| Q1 24 | -179.0% | -35.4% |
| Q4 25 | -961.9% | -5.6% | ||
| Q3 25 | -2441.5% | -14.4% | ||
| Q2 25 | -445.1% | -19.4% | ||
| Q1 25 | -521.2% | -10.1% | ||
| Q4 24 | -43.4% | 0.3% | ||
| Q3 24 | -30.4% | -3.4% | ||
| Q2 24 | -229.6% | 8.9% | ||
| Q1 24 | -224.0% | -68.8% |
| Q4 25 | $-4.63 | — | ||
| Q3 25 | $-22.17 | — | ||
| Q2 25 | $-7.42 | — | ||
| Q1 25 | $-2.26 | — | ||
| Q4 24 | $8.53 | — | ||
| Q3 24 | $-0.58 | — | ||
| Q2 24 | $-7.67 | $-0.15 | ||
| Q1 24 | $-8.33 | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-207.8M | $9.0M |
| Total Assets | $365.0M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $3.4M | ||
| Q3 25 | $878.0K | $2.3M | ||
| Q2 25 | $4.1M | $1.1M | ||
| Q1 25 | $5.8M | $1.8M | ||
| Q4 24 | $3.3M | $2.0M | ||
| Q3 24 | $77.0K | $2.5M | ||
| Q2 24 | $6.9M | $2.4M | ||
| Q1 24 | $1.8M | $2.1M |
| Q4 25 | $-207.8M | $9.0M | ||
| Q3 25 | $-176.9M | $7.2M | ||
| Q2 25 | $-249.0M | $6.1M | ||
| Q1 25 | $-211.5M | $665.8K | ||
| Q4 24 | $-192.6M | $1.8M | ||
| Q3 24 | $-211.3M | $2.0M | ||
| Q2 24 | $-214.7M | $3.0M | ||
| Q1 24 | $-189.8M | $3.1M |
| Q4 25 | $365.0M | $11.8M | ||
| Q3 25 | $275.9M | $10.4M | ||
| Q2 25 | $83.8M | $9.9M | ||
| Q1 25 | $79.0M | $10.9M | ||
| Q4 24 | $93.0M | $11.5M | ||
| Q3 24 | $100.4M | $10.6M | ||
| Q2 24 | $104.5M | $13.8M | ||
| Q1 24 | $91.2M | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-17.5M | $-812.5K |
| Free Cash FlowOCF − Capex | — | $-977.3K |
| FCF MarginFCF / Revenue | — | -19.5% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-17.5M | $-812.5K | ||
| Q3 25 | $8.2M | $-240.7K | ||
| Q2 25 | $7.0M | $-704.2K | ||
| Q1 25 | $6.0M | $-189.5K | ||
| Q4 24 | $2.5M | $-317.9K | ||
| Q3 24 | $5.1M | $167.4K | ||
| Q2 24 | $2.3M | $289.8K | ||
| Q1 24 | $9.4M | $-704.1K |
| Q4 25 | — | $-977.3K | ||
| Q3 25 | — | $-243.6K | ||
| Q2 25 | — | $-705.7K | ||
| Q1 25 | — | $-205.0K | ||
| Q4 24 | — | $-482.3K | ||
| Q3 24 | — | $157.4K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-708.7K |
| Q4 25 | — | -19.5% | ||
| Q3 25 | — | -5.2% | ||
| Q2 25 | — | -15.3% | ||
| Q1 25 | — | -4.3% | ||
| Q4 24 | — | -9.4% | ||
| Q3 24 | — | 3.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -16.2% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCLX
Segment breakdown not available.
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
